drug-repurposing-strategist

Drug repurposing for oral mucositis identifies approved candidates by matching OM-associated genes to drug targets and validating mechanism direction. It cross-references OM gene-disease CSV data with approved drug target, mechanism, indication, and safety CSV files to produce structured candidate reports and scores.

Target overlap analysis in drug repurposing identifies disease-relevant genes and maps them to approved drugs via drug-target data. This shortlists candidates with plausible target engagement by systematically linking disease-associated biology to targets and mechanisms of already approved drugs.

You rank drug repurposing candidates using a weighted framework covering overlap strength, safety context, route compatibility, and evidence level. This feasibility scoring produces consistent candidate reports and scores for systematic OM candidate prioritization and network-pharmacology exploration.

Yes, you can generate testable repurposing hypotheses for oral mucositis from CSV datasets by cross-referencing OM gene-disease data with approved drug target, mechanism, indication, and safety CSV files. This produces ranked candidate reports for evidence-grounded hypothesis formulation.

Drug repurposing checks mechanism of action alignment by verifying whether each candidate's mechanism direction fits what oral mucositis needs across inflammatory, oxidative, and healing phases. This mechanism validation ensures candidates match the disease's biological requirements.

For systematic oral mucositis candidate generation, you need processed CSV datasets under data/processed/ containing OM gene-disease associations, plus approved drug target, mechanism, indication, and safety CSV files. These inputs enable target overlap analysis and ranked prioritization.